Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Core Insights - Tevogen Bio Holdings Inc. has secured $1 million in funding to enhance its artificial intelligence-driven drug discovery program, Tevogen.AI [1][6] - The funding is part of a larger agreement with KRHP LLC, which could provide up to $10 million in non-dilutive funding, including $2 million received in January 2025 [2][6] - Tevogen.AI's recent patent publication for its machine learning technology aims to improve targeted therapies for cancers and infectious diseases [2] Financial Position - The company is well-capitalized, with access to a $36 million line of credit, ensuring it can execute its growth strategy effectively [3][6] - The total potential funding from KRHP LLC, including the recent $1 million, amounts to $10 million, which will support the advancement of Tevogen.AI [2][6] Strategic Focus - The funding will be utilized to accelerate Tevogen.AI's capabilities, focusing on enhancing target discovery, shortening development timelines, and improving treatment accessibility for large patient populations [2][6]